Background

Treatment of Ewing sarcoma (ES) requires multidisciplinary approach and deficiencies in treatment adversely affect the results. This study included patients diagnosed with ES and aimed to determine the factors affecting prognosis and investigate the efficacy of replacing actinomycin-D with carboplatin in consolidation treatment.

Methods

Eighty-two pediatric ES patients diagnosed at a single institution between 2005 and 2020 were retrospectively evaluated. Clinical and epidemiological features, treatment modalities, prognostic criteria, and overall survival (OS) rates of patients revieved. In consolidation treatment, 22 patients were treated with actinomycin-D and 32 patients with carboplatin (500 mg/m²/dose), 24 patients could not receive consolidation treatment. The 5- and 10-year OS rates of the patients were compared.

Results

The 5- and 10-year OS rates of the 82 patients with ES were 46% and 40%, respectively. The 5-year OS rates in the group with localized disease (n = 55) and metastasis (n = 27) at diagnosis were 54% and 26%, respectively (p = 0.006). When evaluated according to the consolidation treatment administered both the 5- and 10-year OS rates of the patients receiving actinomycin-D were 50%. The 5-year OS rate was 58% in the carboplatin group, and the 5- and 10-year OS rates of patients that did not receive consolidation treatment was 20%.

Conclusions

Survival was significantly worse in the group that did not receive consolidation treatment. Furthermore, our results suggested that carboplatin could be used effectively as an alternative to actinomycin-D in ES consolidation treatment.

中文翻译：

---

卡铂替代放线菌素-D在尤文肉瘤巩固治疗中的疗效：单中心经验

背景

尤文肉瘤 (ES) 的治疗需要多学科方法，治疗不足会对结果产生不利影响。本研究纳入诊断为 ES 的患者，旨在确定影响预后的因素，并探讨在巩固治疗中用卡铂替代放线菌素-D 的疗效。

方法

回顾性评估了 2005 年至 2020 年间在单一机构诊断出的 82 名儿科 ES 患者。审查的患者的临床和流行病学特征、治疗方式、预后标准和总生存率 (OS)。巩固治疗中，放线菌素-D治疗22例，卡铂治疗32例（500mg/m ² /剂），24例未接受巩固治疗。比较了患者的 5 年和 10 年 OS 率。

结果

82 名 ES 患者的 5 年和 10 年 OS 率分别为 46% 和 40%。诊断时局部疾病（n = 55）和转移（n = 27）组的 5 年 OS 率分别为 54% 和 26%（p = 0.006）。当根据巩固治疗进行评估时，接受放线菌素-D 的患者的 5 年和 10 年 OS 率为 50%。卡铂组的 5 年 OS 率为 58%，未接受巩固治疗的患者的 5 年和 10 年 OS 率为 20%。

结论

未接受巩固治疗组的生存率明显更差。此外，我们的研究结果表明，卡铂可以有效地用作 ES 巩固治疗中放线菌素-D 的替代品。